Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

Non-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous histological group which is 20–25% of those with renal cell carcinoma (RCC). Patients with nccRCC have limited therapeutic options due to their exclusion from phase III randomized trials. The aim of the present study was to inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Stellato, Marco, Buti, Sebastiano, Maruzzo, Marco, Bersanelli, Melissa, Pierantoni, Francesco, De Giorgi, Ugo, Di Napoli, Marilena, Iacovelli, Roberto, Vitale, Maria Giuseppa, Ermacora, Paola, Malgeri, Andrea, Maiorano, Brigida Anna, Prati, Veronica, Mennitto, Alessia, Cavo, Alessia, Santoni, Matteo, Carella, Claudia, Fratino, Lucia, Procopio, Giuseppe, Verzoni, Elena, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862874/
https://www.ncbi.nlm.nih.gov/pubmed/36674615
http://dx.doi.org/10.3390/ijms24021096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862874/
https://www.ncbi.nlm.nih.gov/pubmed/36674615
http://dx.doi.org/10.3390/ijms24021096

Ejemplares similares